HUP0300434A3 - Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them - Google Patents

Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HUP0300434A3
HUP0300434A3 HU0300434A HUP0300434A HUP0300434A3 HU P0300434 A3 HUP0300434 A3 HU P0300434A3 HU 0300434 A HU0300434 A HU 0300434A HU P0300434 A HUP0300434 A HU P0300434A HU P0300434 A3 HUP0300434 A3 HU P0300434A3
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
tyrosine kinase
kinase inhibitors
Prior art date
Application number
HU0300434A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of HUP0300434A2 publication Critical patent/HUP0300434A2/hu
Publication of HUP0300434A3 publication Critical patent/HUP0300434A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0300434A 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them HUP0300434A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000106836 2000-04-07
PCT/JP2001/002937 WO2001077107A1 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
HUP0300434A2 HUP0300434A2 (hu) 2003-06-28
HUP0300434A3 true HUP0300434A3 (en) 2004-11-29

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300434A HUP0300434A3 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (2) US6716863B2 (hu)
EP (1) EP1268473A1 (hu)
KR (1) KR20020028865A (hu)
CN (1) CN1444582A (hu)
AU (1) AU2001244726A1 (hu)
BR (1) BR0109851A (hu)
CA (1) CA2404760A1 (hu)
CO (1) CO5261589A1 (hu)
CZ (1) CZ20023264A3 (hu)
EE (1) EE200200576A (hu)
HU (1) HUP0300434A3 (hu)
IL (1) IL152115A0 (hu)
MX (1) MXPA02009621A (hu)
NO (1) NO20024742L (hu)
OA (1) OA12244A (hu)
PE (1) PE20011178A1 (hu)
PL (1) PL365787A1 (hu)
SK (1) SK14132002A3 (hu)
WO (1) WO2001077107A1 (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004999A (en) * 1998-10-08 2000-04-26 Takeda Chemical Industries Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independentcancer
WO2002006249A1 (fr) * 2000-07-19 2002-01-24 Takeda Chemical Industries, Ltd. Procede de fabrication d'un derive de 1,2,3 triasol substitue en position 1
EP1382350A4 (en) * 2001-04-25 2006-01-04 Takeda Pharmaceutical MEANS AGAINST THE PROPHYLAXIS BEFORE POSTOPERATIVE REPEAT OF PREMOPEOPAUSAL BREAST CANCER
WO2002087619A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
WO2002087618A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
WO2003031442A1 (fr) * 2001-10-05 2003-04-17 Takeda Chemical Industries, Ltd. Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
WO2003045929A1 (fr) * 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
WO2003059907A1 (fr) * 2002-01-17 2003-07-24 Takeda Chemical Industries, Ltd. Composes heterocycliques azotes : procede de preparation et d'utilisation
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
MXPA05006513A (es) * 2002-12-16 2005-09-08 Kissei Pharmaceutical Farmaco solido para uso oral.
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200423931A (en) * 2003-04-30 2004-11-16 Hoffmann La Roche Novel aniline derivatives, their manufacture and use as pharmaceutical agents
US7247649B2 (en) * 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200612914A (en) 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200533346A (en) * 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
CA2561203A1 (en) * 2004-04-02 2005-10-20 F. Hoffmann-La Roche Ag New process for the preparation of diazine derivatives
US7005526B2 (en) 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7163953B2 (en) 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
US7342030B2 (en) 2004-09-22 2008-03-11 Hoffmann-La Roche Inc. Indole derivatives
TW200626589A (en) * 2004-09-24 2006-08-01 Hoffmann La Roche Azole derivatives, their manufacture and use as pharmaceutical agents
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US7429605B2 (en) 2005-08-04 2008-09-30 Hoffmann-La Roche Inc. Phenylpyridine derivatives
CN101208335A (zh) * 2005-08-08 2008-06-25 霍夫曼-拉罗奇有限公司 吡唑衍生物，它们的制备和作为药剂的应用
CN101233130A (zh) * 2005-09-30 2008-07-30 霍夫曼-拉罗奇有限公司 二嗪唑衍生物，它们的制备和作为药剂的应用
WO2008034579A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
EP2140883B1 (en) 2007-04-20 2012-10-31 Daido Chemical Corporation Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
WO2009113560A1 (ja) 2008-03-12 2009-09-17 武田薬品工業株式会社 縮合複素環化合物
TW201016704A (en) * 2008-09-26 2010-05-01 Takeda Pharmaceutical Prevention and treatment of cancer with RAS gene mutation
WO2010036928A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation)
KR101442069B1 (ko) 2009-09-30 2014-09-18 가부시키가이샤 상기 난용성 물질의 수용해성 개선방법
US8900628B2 (en) 2010-02-26 2014-12-02 Nisshin Kasei Co., Ltd. Hard capsule and method for producing same
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
US9364438B2 (en) 2012-09-26 2016-06-14 Takeda Pharmaceutical Company Limited Process for producing solid particles
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
CA3099440A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506857A (ja) * 1990-04-16 1993-10-07 ローヌ―プーラン　ローラー　インターナショナル　（ホウルディングス）インコーポレイテッド Ｅｇｆレセプタチロシンキナーゼを阻害するスチリル―置換単環式および二環式複素アリール化合物
DE69736642T2 (de) * 1996-07-19 2007-09-20 Takeda Pharmaceutical Co. Ltd. Heterocyclische Verbindungen, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
US20040024035A1 (en) 2004-02-05
EP1268473A1 (en) 2003-01-02
WO2001077107A8 (en) 2003-02-13
PE20011178A1 (es) 2001-11-19
PL365787A1 (en) 2005-01-10
EE200200576A (et) 2004-06-15
HUP0300434A2 (hu) 2003-06-28
SK14132002A3 (sk) 2003-04-01
AU2001244726A1 (en) 2001-10-23
CA2404760A1 (en) 2001-10-18
NO20024742L (no) 2002-11-25
WO2001077107A1 (en) 2001-10-18
OA12244A (en) 2006-05-10
US20020173526A1 (en) 2002-11-21
CZ20023264A3 (cs) 2003-02-12
US6716863B2 (en) 2004-04-06
CN1444582A (zh) 2003-09-24
KR20020028865A (ko) 2002-04-17
IL152115A0 (en) 2003-05-29
MXPA02009621A (es) 2003-05-14
WO2001077107B1 (en) 2001-12-20
CO5261589A1 (es) 2003-03-31
NO20024742D0 (no) 2002-10-02
BR0109851A (pt) 2003-06-03

Similar Documents

Publication Publication Date Title
HUP0300434A3 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0204083A3 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0301117A3 (en) Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
HUP0300565A3 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
IL153997A0 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0203453A3 (en) Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0302487A3 (en) New mandelic acid derivatives and their use as throbin inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0301688A3 (en) Amino alcohol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0301742A3 (en) Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
HUP0103633A2 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
HUP0402245A3 (en) Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
HUP0400989A3 (en) Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0301315A3 (en) Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
HUP0204410A3 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0402454A3 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases, process for their preparation and pharmaceutical compositions containing them
HUP0303016A3 (en) Xanthine phosphodiesterase v inhibitors, process for their preparation and pharmaceutical compositions containing them and their use
AU2002358676A1 (en) Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
HUP0200816A2 (en) Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases, process for their preparation and pharmaceutical compositions containing them
HUP0303737A3 (en) Indolinones, substituted in position 6, and their use as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0303045A3 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204001A3 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303361A3 (en) Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303105A3 (en) Novel aminocyclohexane derivatives, process for their preparation, pharmaceutical compositions containing them and their use